Researchers at Hokkaido University in Japan, in a collaboration with American scientists, may have identified neural crosstalk as the mechanism that drives widespread inflammation in inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and atherosclerosis.
Merck’s cardiopulmonary pipeline is poised to deliver eight potential approvals over the next eight years, bolstering the company’s pipeline and revenue.
Researchers developed a type of nanoparticle that can “eat debris” related to the plaques that cause heart attacks.
The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.
Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.
German drugmaker Bayer moved to tap a potentially lucrative new market opportunity for its blockbuster clot prevention drug Xarelto, requesting approval in Europe to make atherosclerosis patients eligible for treatment.
Many of the same things people should do for a healthy heart – such as exercising, eating well and avoiding cigarettes – can also help protect the brain from cognitive decline and dementia, according to the American Heart Association and the American Stroke Association.
An anti-inflammatory drug developed for cardiac patients has an exciting, yet unintended side effect – possible prevention of lung cancer.
Bayer and Johnson & Johnson’s blockbuster clot prevention drug Xarelto was shown to cut the risk of potentially deadly strokes and heart attacks in patients with severe atherosclerosis by 24 percent, raising the prospects of billions more in sales.
